You just read:

Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

News provided by

Astellas Pharma Inc.

Jul 16, 2019, 08:00 ET